Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Introduction: Non-alcoholic steatohepatitis (NASH) is now the commonest cause of chronic liver disease. Despite this, there are no universally accepted pharmacological therapies for NASH. Liraglutide (Victoza), a human glucagon-like peptide-1 (GLP-1) analogue, has been shown to improve weight loss, glycaemic control and liver enzymes in type 2 diabetes. There is currently a lack of prospective-controlled studies investigating the efficacy of GLP-1 analogues in patients with NASH. Methods and analysis: Liraglutide efficacy and action in NASH (LEAN) is a phase II, multicentre, double-blinded, placebo-controlled, randomised clinical trial designed to investigate whether a 48-week treatment with 1.8 mg liraglutide will result in improvements in liver histology in patients with NASH. Adult, overweight (body mass index ≥25 kg/m 2 ) patients with biopsy-confirmed NASH were assessed for eligibility at five recruitment centres in the UK. Patients who satisfied the eligibility criteria were randomly assigned (1:1) to receive once-daily subcutaneous injections of either 1.8 mg liraglutide or liraglutide-placebo (control). Using A'Hern's single stage phase II methodology (significance level 0.05; power 0.90) and accounting for an estimated 20% withdrawal rate, a minimum of 25 patients were randomised to each treatment group. The primary outcome measure will be centrally assessed using an intention-to-treat analysis of the proportion of evaluable patients achieving an improvement in liver histology between liver biopsies at baseline and after 48 weeks of treatment. Histological improvement will be defined as a combination of the disappearance of active NASH and no worsening in fibrosis. Ethics and dissemination: The protocol was approved by the National Research Ethics Service (East Midlands—Northampton committee; 10/H0402/32) and the Medicines and Healthcare products Regulatory Agency. Recruitment into the LEAN started in August 2010 and ended in May 2013, with 52 patients randomised. The treatment follow-up of LEAN participants is currently ongoing and is due to finish in July 2014. The findings of this trial will be disseminated through peer-reviewed publications and international presentations. Trial registration: clinicaltrials.gov NCT01237119 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Native GLP-1 has a potent blood glucose-lowering action mediated through its ability to induce insulin secretion and reduce glucagon secretion in a glucose-dependent manner, as well as suppressing appetite and slowing gastric emptying.(8) Human GLP-1, however, only has a short half-life (1.”
BackgroundLong-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“Patients with NASH have a higher risk of liver-related mortality than those with simple hepatic steatosis (± mild inflammation).(49) 50 Owing to the long time-span of NASH progression (ie, 10–20 years) to end-stage liver failure/ death it is impractical to perform therapeutic trials with mortality as the primary outco…”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
Validation of a self-administered diet history questionnaire using multiple diet records
Block, G., Woods, M., Potosky, A., & Clifford, C. (1990) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(90)90099-b · Cited by 1,197 · cited 1×
“The Block Brief 2000 FFQ consisted of a well-validated selfadministered questionnaire consisting of 70 food-related questions and took approximately 15 min to complete.(39) Pictures of standardised serving sizes and an American-to-English food translation sheet (ie, ‘Catsup’=tomato ‘Ketchup’) were used to aid completi…”
MethodAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
The Alcohol Use Disorders Identification Test (AUDIT): A review of recent research
Reinert, D. F., & Allen, J. P. (2002) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02534.x · Cited by 1,143
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Research works printed but not linked: 26
- 10.1016/j.jhep.2011.03.020 · DOI · Paper page
- Bellentani, 1994, Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study, Hepatology, 20, 1442, 10.1002/hep.1840200611 · DOI · Paper page
- 10.1002/hep.20466 · DOI · Paper page
- 10.1097/00042737-200411000-00002 · DOI · Paper page
- 10.1053/j.gastro.2010.09.038 · DOI · Paper page
- 10.1053/gast.2002.34168 · DOI · Paper page
- 10.1053/j.gastro.2011.06.061 · DOI · Paper page
- 10.1210/jc.80.3.952 · DOI · Paper page
- 10.1021/jm9909645 · DOI · Paper page
- 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
- 10.1136/bmj.c5062 · doi:10.1136/bmj.c5062
- 10.1016/j.jhep.2010.09.032 · DOI · Paper page
- 10.1152/ajpgi.00274.2011 · DOI · Paper page
- Ellrichmann, 2009, Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis, Am J Gastroenterol, 104, 3112, 10.1038/ajg.2009.444 · DOI
- 10.1111/j.1478-3231.2006.01315.x · DOI · Paper page
- 10.1002/hep.20701 · DOI · Paper page
- 10.1002/hep.24376 · DOI · Paper page
- 10.1016/0168-8278(95)80226-6 · DOI · Paper page
- 10.1002/hep.22724 · DOI · Paper page
- 10.1053/j.gastro.2004.08.052 · DOI · Paper page
- Armstrong MJ Corbett C Hodson J . Operator training requirements and diagnostic accuracy of Fibroscan in routine clinical practice. Postgrad Med J 2013. Published Online First: 7 Aug 2013. doi: 10.1136/postgradmedj-2012-131640 · DOI
- 10.1016/j.jclinepi.2007.08.008 · DOI
- 10.1002/sim.721 · DOI · Paper page
- 10.1056/NEJM200102153440706 · DOI · Paper page
- 10.1056/NEJMoa0907929 · DOI · Paper page
- 10.1002/hep.23314 · DOI · Paper page
Cited by
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Self-citationNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“…the reductions in weight and plasma glucose concentrations were similar among those with improvement in liver histology (‘‘responders’’) versus those without (‘‘non-responders’’), suggesting that part of the beneficial effects of GLP1 analogs may be weight independent (Armstrong et al., 2013).”
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Self-citationXu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Metadata
- Authors
- Armstrong, M. J., Barton, D., Gaunt, P., Hull, D., Guo, K., Stocken, D., Gough, S. C. L., Tomlinson, J. W., Brown, R. M., Hübscher, S. G., Newsome, P. N., & on behalf of the LEAN trial team
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013-11
- Volume
- 3
- Issue
- 11
- Pages
- e003995
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2028279539
- Cited by
- 51
- References
- 27
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. https://app.cochat.ai/papers/10.1136/bmjopen-2013-003995
- The paper
- Armstrong, M. J., Barton, D., Gaunt, P., Hull, D., Guo, K., Stocken, D., Gough, S. C. L., Tomlinson, J. W., Brown, R. M., Hübscher, S. G., Newsome, P. N., & on behalf of the LEAN trial team. (2013). Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. https://doi.org/10.1136/bmjopen-2013-003995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.